<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ribavirin (oral inhalation): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ribavirin (oral inhalation): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ribavirin (oral inhalation): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="105699" href="/d/html/105699.html" rel="external">see "Ribavirin (oral inhalation): Drug information"</a> and <a class="drug drug_patient" data-topicid="106473" href="/d/html/106473.html" rel="external">see "Ribavirin (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F45623568"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of ribavirin in patients requiring mechanical ventilator assistance should be undertaken only by health care providers and support staff familiar with this mode of administration and the specific ventilator being used. Strict attention must be paid to procedures that have been shown to minimize the accumulation of drug precipitate, which can result in mechanical ventilator dysfunction and associated increases in pulmonary pressures.</p>
<p style="text-indent:-2em;margin-left:2em;">Sudden deterioration of respiratory function has been associated with the initiation of ribavirin use in infants. Carefully monitor respiratory function during treatment. If the initiation of ribavirin treatment appears to produce sudden deterioration of respiratory function, stop treatment and reinstitute only with extreme caution, continuous monitoring, and consideration of coadministration of bronchodilators.</p>
<p style="text-indent:-2em;margin-left:2em;">Aerosolized ribavirin is not indicated for use in adults. Be aware that ribavirin has been shown to produce testicular lesions in rodents and to be teratogenic in all animal species in which adequate studies have been conducted (rodents and rabbits).</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45623576"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Virazole</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872083"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Virazole</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F45665693"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihepaciviral, Nucleoside (Anti-HCV)</span></li></ul></div>
<div class="block dop drugH1Div" id="F45623631"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0391a139-54d3-4c7f-8104-56634af3c33f">Respiratory syncytial virus infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory syncytial virus (RSV) infection: Note:</b> Due to lack of clinically significant effect on outcomes, the AAP recommends against routine use of ribavirin to treat RSV. Additionally, concerns exist regarding cost and potential toxicity in exposed health care personnel (<i>Red Book</i> [AAP 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Aerosol inhalation: <b>Note:</b> Dose actually delivered to the patient will depend on patient's minute ventilation.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous aerosolization: Infants and Children: 6 <b>g</b> administered over 12 to 18 hours/day for 3 to 7 days using Bausch Health small particle aerosol generator (SPAG-2).</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent aerosolization: Very limited data available: Infants, Children, and Adolescents: 2,000 mg over 2 to 3 hours 3 times daily for 2 to 10 days has been used to permit easier accessibility for patient care and limit environmental exposure of health care workers (Chemaly 2014; Dallas 2020; Englund 1994). Utilization of the SPAG-2 is the most common method of administration; however, use of a vibrating mesh micropump nebulizer (Aerogen Solo) has also been described (Dallas 2020; Walsh 2016).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192771"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51192772"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F45623632"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="105699" href="/d/html/105699.html" rel="external">see "Ribavirin (oral inhalation): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a42b89a7-1af3-4a5d-b4a2-eee0a9899de6">Respiratory syncytial virus infection in hematopoietic cell or heart/lung transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory syncytial virus infection in hematopoietic cell or heart/lung transplant recipients (off-label use):</b>
<b>Note:</b> May use in combination with intravenous immune globulin (IGIV), methylprednisolone, and palivizumab. Dosage and protocol may be institution-specific (Boeckh 2007; Chemaly 2006; Liu 2010; Shah 2013; Whimbey 1995). Pretreatment with albuterol may be necessary (Hynicka 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral inhalation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanically-ventilated patients:</i> Continuous dosing: 6 g over 12 to 18 hours daily (Chemlay 2006; Ghosh 2000; Hynicka 2012; Shah 2013; Whimbey 1995)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-mechanically-ventilated patients: </i>Intermittent dosing: 2 g (over 2 to 4 hours) every 8 hours (Boeckh 2007; Hynicka 2012; Liu 2010) <b>or</b> 6 g (over 2 to 6 hours) every 6 to 8 hours via a small particle aerosol generator (SPAG-2) nebulizer (mask or hood) (Chemlay 2006; Ghosh 2000; Shah 2013; Trang 2018)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989968"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987297"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F45623597"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bigeminy, bradycardia, chest pain, hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, atelectasis, bacterial pneumonia, bronchospasm, cyanosis, dyspnea, hypoventilation, pneumothorax, pulmonary complications (ventilator dependence), pulmonary edema, severe dyspnea (worsening of respiratory status)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anemia, hemolytic anemia, reticulocytosis</p></div>
<div class="block coi drugH1Div" id="F45623594"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant</p></div>
<div class="block war drugH1Div" id="F45623595"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory deterioration:<b> [US Boxed Warning]: Sudden respiratory deterioration has been observed during the initiation of aerosolized ribavirin in infants; carefully monitor during treatment. If deterioration of respiratory function occurs, stop treatment; reinstitute with extreme caution, continuous monitoring, and consider concomitant administration of bronchodilators.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy: <b>[US Boxed Warning]: Significant teratogenic and/or embryocidal effects have been observed in all animal species with adequate studies. Use is contraindicated in pregnant women.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inhalation: <b>[US Boxed Warning]: Use with caution in patients requiring assisted ventilation because precipitation of the drug in the respiratory equipment may interfere with safe and effective patient ventilation; sudden deterioration of respiratory function has been observed;</b> monitor carefully in patients with COPD and asthma for deterioration of respiratory function.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878812"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Sudden respiratory deterioration has been observed during the initiation of aerosolized ribavirin in infants; carefully monitor infants. If deterioration of respiratory function occurs, stop treatment; reinstitute with extreme caution, continuous monitoring, and consider concomitant administration of bronchodilators. </p></div>
<div class="block foc drugH1Div" id="F45623649"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Virazole: 6 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F45623579"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F45623651"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ribavirin Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 g (per each): $24,000.00 - $27,600.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Virazole Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 g (per each): $29,953.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872084"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Virazole: 6 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614634"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Aerosolize with Bausch Health small particle aerosol generator (SPAG-2). Ribavirin should be administered in negative-pressure or other well-ventilated rooms (at least 6 air changes/hour). Additional precautions to limit exposure to health care personnel include the use of scavenging devices or respirator masks and turning off the aerosolizer for 5 to 10 minutes prior to prolonged patient contact. Solutions in SPAG-2 unit should be discarded at least every 24 hours and when the liquid level is low before adding newly reconstituted solution. Should not be mixed with other aerosolized medication.</p>
<p style="text-indent:-2em;margin-left:4em;">The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">Non-mechanically ventilated patients: Administer via an infant oxygen hood; if not available, may use an oxygen tent or face mask.</p>
<p style="text-indent:-2em;margin-left:6em;">Mechanically ventilated patients: Ribavirin can potentially be deposited in the ventilator delivery system, which can lead to mechanical ventilator dysfunction and increased pulmonary pressures. To minimize accumulation of drug precipitate, use and frequently change (every 4 hours) filters in the expiratory line, use water column pressure release valves, frequently monitor devices, and verify that ribavirin crystals have not accumulated within circuit. Endotracheal tubes should be suctioned every 1 to 2 hours and pulmonary pressures should be monitored every 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent inhalation: Utilization of the SPAG-2 as described above is the most common method of administration; however, use of a vibrating mesh micropump nebulizer (Aerogen Solo) has also been described (Dallas 2020; Walsh 2016).</p></div>
<div class="block adm drugH1Div" id="F45623638"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral inhalation: Ribavirin should be administered in well-ventilated rooms (at least 6 air changes/hour). In mechanically ventilated patients, ribavirin can potentially be deposited in the ventilator delivery system depending on temperature, humidity, and electrostatic forces; this deposition and drug precipitation can lead to malfunction or obstruction of the expiratory valve, resulting in inadvertently high positive end-expiratory pressures. The use of one-way valves in the inspiratory lines, a breathing circuit filter in the expiratory line, and frequent monitoring and filter replacement have been effective in preventing these problems. Solutions in SPAG-2 unit should be discarded at least every 24 hours and when the liquid level is low before adding newly reconstituted solution. Should not be mixed with other aerosolized medications. Environmental services/infection control should be notified of ribavirin inhaled administration to any patient. The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol.</p></div>
<div class="block hazard drugH1Div" id="F49133471"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for preparation; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a powder or solution for inhalation or an aerosol treatment; if there is potential for inhalation, respiratory protections is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F45623610"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Store vials in a dry place at 15°C to 30°C (59°F to 86°F). Reconstituted solution is stable for 24 hours at room temperature.</p></div>
<div class="block usep drugH1Div" id="F53571332"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hospitalized patients with severe lower respiratory tract respiratory syncytial virus (RSV) infections (FDA approved in infants and young children). <b>Note:</b> The AAP recommends against routine use of ribavirin to treat RSV because it has no clinically significant impact on outcomes (<i>Red Book</i> [AAP 2018]).</p></div>
<div class="block mst drugH1Div" id="F45623569"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ribavirin may be confused with riboflavin, rifAMPin, Robaxin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45623604"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45623601"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Ribavirin (Oral Inhalation) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Oral Inhalation) may increase serum concentrations of the active metabolite(s) of Didanosine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: May enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49321991"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in females who may become pregnant.</p></div>
<div class="block pri drugH1Div" id="F45623591"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in females who are pregnant. <b>[US Boxed Warning]: Aerosolized ribavirin is not indicated for use in adults. Be aware that ribavirin has been shown to produce testicular lesions in rodents and to be teratogenic in all animal species in which adequate studies have been conducted (rodents and rabbits).</b> The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol; potential occupational exposure may be greatest if administration is via oxygen tent or hood, and lower if administered via mechanical ventilation. The minimum interval following exposure to ribavirin inhalation prior to pregnancy is not known.</p></div>
<div class="block mopp drugH1Div" id="F53571333"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory function, CBC with differential (hemoglobin, reticulocyte count).</p></div>
<div class="block pha drugH1Div" id="F45623614"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis</p></div>
<div class="block phk drugH1Div" id="F45623617"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Inhalation: Systemic; dependent upon respiratory factors and method of drug delivery; maximal absorption occurs with the use of aerosol generator via endotracheal tube; highest concentrations in respiratory tract and erythrocytes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Occurs intracellularly and may be necessary for drug action; metabolized hepatically to deribosylated ribavirin (active metabolite) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 64% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory tract secretions: Infants and Children 6 weeks to 7 years: ~2 hours (Englund 1990)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plasma: Infants and Children: Inhalation: 9.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Inhalation: At end of inhalation period</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Inhalation: Urine (40% as unchanged drug and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45855040"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Li li ning</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Virazole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8545210">
<a name="8545210"></a>American Academy of Pediatrics Committee on Infectious Diseases, “Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections,” <i>Pediatrics</i>, 1996, 97(1):137-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/8545210/pubmed" id="8545210" target="_blank">8545210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8361820">
<a name="8361820"></a>American Academy of Pediatrics Committee on Infectious Diseases, “Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection,” <i>Pediatrics</i>, 1993, 92(3):501-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/8361820/pubmed" id="8361820" target="_blank">8361820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17173225">
<a name="17173225"></a>Boeckh M, Englund J, Li Y, et al, “Randomized Controlled Multicenter Trial of Aerosolized Ribavirin For Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients,” <i>Clin Infect Dis</i>, 2007, 44(2):245-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/17173225/pubmed" id="17173225" target="_blank">17173225</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Chemaly RF, Ghantoji SS, Shah DP, et al. Respiratory syncytial virus infections in children with cancer. <i>J Pediatr Hematol Oncol</i>. 2014;36(6):e376-e381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/24327130/pubmed" id="24327130" target="_blank">24327130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16974212">
<a name="16974212"></a>Chemaly RF, Ghosh S, Bodey GP, et al, “Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplant Recipients: A Retrospective Study at a Major Cancer Center,” <i>Medicine (Baltimore)</i>, 2006, 85(5):278-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/16974212/pubmed" id="16974212" target="_blank">16974212</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dallas RH, Rains JK, Wilder K, et al. The Aerogen<sup>®</sup> Solo is an alternative to the small particle aerosol generator (SPAG-2) for administration of inhaled ribavirin. <i>Pharmaceutics</i>. 2020;12(12):1163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/33260359/pubmed" id="33260359" target="_blank">33260359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7931890">
<a name="7931890"></a>Englund JA, Piedra PA, Ahn YM, et al, “High-Dose, Short-Duration Ribavirin Aerosol Therapy Compared With Standard Ribavirin Therapy in Children With Suspected Respiratory Syncytial Virus Infection,” <i>J Pediatr</i>, 1994, 125:635-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/7931890/pubmed" id="7931890" target="_blank">7931890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2380833">
<a name="2380833"></a>Englund JA, Piedra PA, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection<i>. J Pediatr</i>. 1990;117(2 Pt 1):313-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/2380833/pubmed" id="2380833" target="_blank">2380833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30202920">
<a name="30202920"></a>Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. <i>Clin Infect Dis</i>. 2019;68(10):1641-1649.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/30202920/pubmed" id="30202920" target="_blank">30202920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10745261">
<a name="10745261"></a>Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. <i>Bone Marrow Transplant</i>. 2000;25(7):751-755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/10745261/pubmed" id="10745261" target="_blank">10745261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22395247">
<a name="22395247"></a>Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. <i>Ann Pharmacother</i>. 2012;46(4):558-566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/22395247/pubmed" id="22395247" target="_blank">22395247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ison.2019">
<a name="Ison.2019"></a>Ison MG. Viral infections following lung transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2139930">
<a name="2139930"></a>Janai HK, Marks MI, Zaleska M, et al, “Ribavirin: Adverse Drug Reactions 1986 to 1988,” <i>Pediatr Infect Dis J</i>, 1990, 9(3):209-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/2139930/pubmed" id="2139930" target="_blank">2139930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19761558">
<a name="19761558"></a>Liu V, Dhillon GS, and Weill D, “A Multi-Drug Regimen for Respiratory Syncytial Virus and Parainfluenza Virus Infections in Adult Lung and Heart-Lung Transplant Recipients,” <i>Transp Infect Dis</i>, 2010, 12(1):38-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/19761558/pubmed" id="19761558" target="_blank">19761558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8143465">
<a name="8143465"></a>Meert KL, Sarnaik AP, Gelmini MJ, et al, “Aerosolized Ribavirin in Mechanically Ventilated Children With Respiratory Syncytial Virus Lower Respiratory Tract Disease: A Prospective, Double-Blind, Randomized Trial,” <i>Crit Care Med</i>, 1994, 22(4):566-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/8143465/pubmed" id="8143465" target="_blank">8143465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9421694">
<a name="9421694"></a>Ottolini MG and Hemming VG, “Prevention and Treatment Recommendations for Respiratory Syncytial Virus Infection. Background and Clinical Experience 40 Years After Discovery,” <i>Drugs</i>, 1997, 54(6):867-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/9421694/pubmed" id="9421694" target="_blank">9421694</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ribavirin [prescribing information]. Louisville, KY: Cameron Pharmaceuticals; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23572228">
<a name="23572228"></a>Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. <i>J Antimicrob Chemother</i>. 2013;68(8):1872-1880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/23572228/pubmed" id="23572228" target="_blank">23572228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1904551">
<a name="1904551"></a>Smith DW, Frankel LR, Mathers LH, et al, “A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection,” <i>N Engl J Med</i>, 1991, 325(1):24-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/1904551/pubmed" id="1904551" target="_blank">1904551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29360277">
<a name="29360277"></a>Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. <i>Transpl Infect Dis</i>. 2018;20(2):e12844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/29360277/pubmed" id="29360277" target="_blank">29360277</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7853967">
<a name="7853967"></a>Van Bever HP, Desager KS, Van Hoeck K, et al, “Water Intoxication After Nebulised Tribavirin,” <i>Lancet</i>, 1995, 345(8947):451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/7853967/pubmed" id="7853967" target="_blank">7853967</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Virazole (ribavirin) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; May 2019.</div>
</li>
<li>
<div class="reference">
                  Walsh BK, Betit P, Fink JB, Pereira LM, Arnold J. Characterization of ribavirin aerosol with small particle aerosol generator and vibrating mesh micropump aerosol technologies. <i>Respir Care</i>. 2016;61(5):577-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/26932383/pubmed" id="26932383" target="_blank">26932383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8535312">
<a name="8535312"></a>Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. <i>Bone Marrow Transplant</i>. 1995;16(3):393-399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ribavirin-oral-inhalation-pediatric-drug-information/abstract-text/8535312/pubmed" id="8535312" target="_blank">8535312</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105700 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
